This year’s recipient of the TAT Honorary Award Prof. Ruth Plummer, retraces the most significant milestones of her career in early phase studies 

Sex- and gender-sensitive medicine postulates that differences in biological sex, gender identity, role and relations all impact health and disease, and may have implications for prevention, screening, diagnosis and treatment. Its goal is to learn from these differences to improve care and treatment for men and women.

In cancer research, academy and industry still work in silos but there is room for improvement, and more successful partnership can rise from an in-depth acknowledgement of needs, shared area of interests and drivers for change. A very first step towards this direction has been taken by the Clinical Academic Cancer Research Forum (CAREFOR) – a multi-stakeholder platform aiming to improve academic cancer research in Europe – which conducted an analysis of current models, challenges and effective strategies for academic-industry research together with selected industry representatives.  The paper, which has been recently published on ESMO Open, (1) is a call to action to all oncology communities to join their efforts. Commenting on the paper, Professor Eric Van Cutsem from University of Leuven, Belgium, shares his perspectives on how investing in collaborative trials may be strategic for the benefit of patients.

The intriguing possibility that altering the microbiome might offer a way of augmenting response to immunotherapy is one of the pioneering new treatment options being explored in oncology.

TAT 2020 Honorary Award recipient Lillian L. Siu, Professor at the University of Toronto and Medical Oncologist at the Princess Margaret Cancer Centre, Toronto, explains the latest progress being made in using ‘bugs as drugs’.